(Q37165875)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

Getting specific: monoclonal antibodies in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Andreas Lutterotti

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

538-547

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json

Continuous cultures of fused cells secreting antibody of predefined specificity

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Monoclonal antibody successes in the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Selecting and screening recombinant antibody libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Human antibodies from transgenic animals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Potent antibody therapeutics by design

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Antibody humanization: a case of the 'Emperor's new clothes'?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Immunogenicity of engineered antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Engineering antibodies for clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Immunology of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

An open trial of OKT3 in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Depletion of Vbeta5.2/5.3 T cells with a humanized antibody in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

"Thinking without thinking" about natalizumab and PML.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Immune surveillance in multiple sclerosis patients treated with natalizumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

CAMPATH: from concept to clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Sites and stages of autoreactive B cell activation and regulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

The spectrum of neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

An open label study of the effects of rituximab in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Inhibition of Nogo: a key strategy to increase regeneration, plasticity and functional recovery of the lesioned central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Antibody cocktails: next-generation biopharmaceuticals with improved potency

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970110-8

7 January 2021

10.1016/S1474-4422(08)70110-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485317%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference